ICOS

Ocean Biomedical and Aesther Healthcare Acquisition Corp. Announce Publication of Discovery Data for a Major Anti-Tumor Pathway in Malignant Melanoma and Other Cancers

Retrieved on: 
Monday, January 30, 2023
B7-1, Antibody, Fibrosis, Metastasis, Skin cancer, Melanoma, Cluster, Journal, PD-1, Large-cell lung carcinoma, Cancer, Biology, NSCLC, B7-2, RI, Outline, Lung, PTEN, Patient, ICOS, CD28, Apoptosis, Glioblastoma, CTLA4, Neoplasm, Research, Vaccine, Medical imaging, Immunology, CHI3L1, Medicine, Frontiers

Providence, RI and New York, NY, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical and Aesther Healthcare Acquisition Corp. (NASDAQ: AEHA) announced today the discovery of a second major anti-tumor pathway and therapeutic approach that targets CTLA-4, inhibiting the metastasis of malignant melanoma cells to the lung using a novel bispecific antibody approach. This major regulating mechanism discovery, recently published in Frontiers in Immunology, by Ocean Biomedical’s Scientific Co-founder and Brown University’s Emeritus Dean of Medicine and Biological Sciences, Dr. Jack A. Elias, builds on his team’s prior discoveries that target Chitinase 3-like-1 (CHI3LI) and its role in inhibiting T-cell proliferation. Additionally, this promising research reveals a third anti-tumor pathway targeting T-cell co-stimulation using the inducible co-stimulator (ICOS) and its ligand ICOSL, and Cluster of Differentiation 28 (CD28) and its ligands B7-1 and B7-2. Ocean Biomedical’s novel approach to tumor suppression, focused on controlling CHI3LI, other immune checkpoint inhibitors, and T-cell co-stimulators, has potential application for tumor suppression across multiple cancer pathways.

Key Points: 
  • Ocean Biomedical’s novel approach to tumor suppression, focused on controlling CHI3LI, other immune checkpoint inhibitors, and T-cell co-stimulators, has potential application for tumor suppression across multiple cancer pathways.
  • “If you control CH3L1, you don’t just control one anti-cancer pathway, you simultaneously control many anti-cancer pathways.
  • Malignant melanoma, a very serious skin cancer with a 22.5% five-year survival for patients with Stage IV disease, can metastasize to other organs.
  • We look forward to working with Ocean Biomedical to bring all of these therapies to patients, for the long-term shareholder value and the continued advancement of medical science.”

Xencor Highlights 2023 Corporate Priorities and Provides Portfolio Updates

Retrieved on: 
Monday, January 9, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, IND, Degenerative disease, Autoimmune disease, Janssen, Hoffmann-La Roche, Ipilimumab, Lymphoma, Ovarian cancer, Monoclonal antibody, Janssen Biotech, Bispecific monoclonal antibody, CD28, Cytokine, ICOS, Tumor microenvironment, Psoriasis, ENPP3, RCC, Biology, CLDN6, NK, Immune system, Protein engineering, Ligand, Patient, Genentech, CD3, Atopic dermatitis, Research, Cancer, Claudin, CLDN9, Antibody, Lenalidomide, MCRPC, Vaccine, Pharmaceutical industry, Medicine, Medical imaging, Regulatory T cell

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced 2023 corporate priorities and provided multiple clinical development updates.

Key Points: 
  • Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced 2023 corporate priorities and provided multiple clinical development updates.
  • “We are building on this momentum in 2023, progressing our clinical portfolio internally and with our co-development partners, including four bispecific antibody programs targeting solid tumors.
  • Xencor plans to:
    Continue enrolling patients into the Phase 1b, multiple-ascending dose study in patients with atopic dermatitis and psoriasis.
  • Xencor ended the fourth quarter of 2022 with unaudited cash, cash equivalents, receivables and marketable debt securities totaling approximately $610 million.

Jounce Therapeutics Presents INNATE Phase 1 and SELECT Clinical Trial data at the European Society of Medical Oncology Immuno-Oncology (ESMO - IO) Annual Congress

Retrieved on: 
Thursday, December 8, 2022
RNA, Immunotherapy, Annual report, Security (finance), SD, Ovarian cancer, Marketing, LILRB2, Hypothyroidism, Induction, Nivolumab, RO, Society for Immunotherapy of Cancer, Interval (mathematics), Clinical trial, Tumor microenvironment, Inflammation, Macrophage, Safety, Congress, Cancer, PD-1, Large-cell lung carcinoma, Gilead Sciences, Trae tha Truth, CI, PFS, PD-L1, Ligand, CCR8, NSCLC, SELECT, RECIST, ORR, Immune system, Patient, ILT4, Bone pain, ICOS, Poster, Immunoglobulin G, Pharmacokinetics, Toxic epidermal necrolysis, CD4, IO, Cachexia, Appendix, Therapy, Partnership, Pharmaceutical industry, Vaccine, Fourth, fifth, and sixth derivatives of position

CAMBRIDGE, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today reported new clinical data from the INNATE trial with JTX-8064 and pimi and the SELECT trial with vopra and pimi in two poster presentations at the ESMO-IO 2022 Annual Congress being held in Geneva, Switzerland.

Key Points: 
  • Pimivalimab is currently being assessed in the INNATE Phase 1/2 trial (NCT04669899) in combination with JTX-8064, a LILRB2 (ILT4) inhibitor.
  • Pimivalimab is also being assessed in the SELECT Phase 2 clinical trial (NCT04549025) in combination with vopratelimab.
  • Pimivalimab is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce’s broader pipeline.
  • Although Jounce believes that the expectations reflected in the forward-looking statements are reasonable, Jounce cannot guarantee such outcomes.

Aimco Files Investor Presentation Highlighting Successful Execution of Value-Add Strategy Under Leadership of New Board of Directors and Management Team

Retrieved on: 
Monday, November 21, 2022
Residential Building & Real Estate, Commercial Building & Real Estate, Construction & Property, REIT, Baylor University, Investment, Sale, Annual general meeting, Lazard, NAV, FTSE, Partnership, Russell, AIR, ICOS, NYSE, Eli Lilly, Western Asset Management Company, Host Hotels & Resorts, Real estate, AIV, Research, Department of Lands building, Alaska Permanent Fund, Real estate investment trust, IRR, Cousins Properties, Marriott International, Green Street, Building, Management, Holding company, Property management, Commercial property, Risk management, Land, Shareholder, Aimco

The presentation is available on the investor relations section of the Companys website.

Key Points: 
  • The presentation is available on the investor relations section of the Companys website.
  • Alongside an all-new executive management team, the Board has overseen the development and successful execution of Aimcos clearly defined value creation strategy following the spin-off of Apartment Income REIT Corp. (AIR) in December 2020.
  • The New Aimco Board is also overseeing the evaluation of a broad range of options to enhance stockholder value.
  • Aimco believes the claims made by Land & Buildings are largely baseless and about the predecessor company with an entirely different leadership team and a substantially different board.

Jounce Therapeutics Reports Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 10, 2022
Investor, European Society for Medical Oncology, Partnership, ICOS, Immunotherapy, Research, Macrophage, Family, G&A, SELECT, Therapy, PD-L1, PD-1, Conference, Society for Immunotherapy of Cancer, ILT4, Security (finance), Review, LILRB4, Marketing, Tumor microenvironment, CCR8, Gilead Sciences, U.S. Securities and Exchange Commission, BTC, Pharmacokinetics, Private Securities Litigation Reform Act, Cancer, Patient, COVID-19, LILRB2, Webcast, Oncology, Neoplasm, HNSCC, Myelocyte, Public expenditure, Poster, Society, Congress, POC, GLOBE, PFS, Head, Intellectual property, Investment, ESMO, Cholangiocarcinoma, Annual report, NASDAQ, Safety, ILT3, Immune system, Heart, Squamous cell carcinoma, SITC, Life insurance, Pharmaceutical industry, Vaccine, IND, Fourth, fifth, and sixth derivatives of position

- Ended the quarter with $130.3 million in cash, cash equivalents and investments -

Key Points: 
  • - Ended the quarter with $130.3 million in cash, cash equivalents and investments -
    CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.
  • Third Quarter 2022 Financial Results:
    Cash position: As of September 30, 2022, cash, cash equivalents and investments decreased to $130.3 million, compared to $220.2 million as of December 31, 2021.
  • License and collaboration revenue: Jounce did not recognize any revenue during the third quarter of 2022 or 2021.
  • Based on its current operating and development plans and cost containment efforts, Jounce is reiterating its financial guidance for 2022.

Jounce Therapeutics earns clinical milestone payment under the CCR8 exclusive license agreement with Gilead Sciences, Inc.

Retrieved on: 
Wednesday, November 2, 2022
Security (finance), Annual report, LILRB2, PD-1, U.S. Securities and Exchange Commission, ILT4, SELECT, Cancer, GLOBE, IND, Program, Macrophage, Immune system, Gilead Sciences, ICOS, NASDAQ, Private Securities Litigation Reform Act, TITR, Therapy, Patient, CCR8, Tumor microenvironment, GILD, Pharmaceutical industry, Fourth, fifth, and sixth derivatives of position

Under the terms of the September 2020 agreement, Gilead invested $35.0 million in Jounces common stock and made an $85.0 million upfront payment to Jounce.

Key Points: 
  • Under the terms of the September 2020 agreement, Gilead invested $35.0 million in Jounces common stock and made an $85.0 million upfront payment to Jounce.
  • Jounce led the development of JTX-1811 through IND clearance, after which Gilead obtained the sole right to develop and commercialize the program.
  • Any milestone or royalty paid to Jounce is subject to certain reductions as described in the license agreement.
  • Although Jounce believes that the expectations reflected in the forward-looking statements are reasonable, Jounce cannot guarantee such outcomes.

Jounce Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10, 2022

Retrieved on: 
Thursday, October 27, 2022
NASDAQ, Investor, Cancer, Gilead Sciences, ILT4, CCR8, Webcast, Tumor microenvironment, ICOS, SELECT, Patient, Immune system, PD-1, GLOBE, Therapy, LILRB2, Macrophage, Pharmaceutical industry, Fourth, fifth, and sixth derivatives of position

Jounce Therapeutics' management team will host a webcast and live conference call at 8:00 a.m.

Key Points: 
  • Jounce Therapeutics' management team will host a webcast and live conference call at 8:00 a.m.
  • To access the conference call, please register here and please be advised to do so at least 10 minutes prior to joining the call.
  • The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the company's website at www.jouncetx.com .
  • Pimivalimab is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounces broader pipeline.

Jounce Therapeutics to Present Multiple Posters at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting and the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) Annual Congress

Retrieved on: 
Thursday, October 20, 2022
ILT4, U.S. Securities and Exchange Commission, Congress, SELECT, Therapy, Macrophage, Neoplasm, SITC, LILRB4, Private Securities Litigation Reform Act, Annual report, NASDAQ, Patient, Research, Security (finance), Annual general meeting, Gilead Sciences, Cancer, Immune system, Tumor microenvironment, ICOS, PD-1, CCR8, Safety, GLOBE, PK, COVID-19, LILRB2, Pharmaceutical industry, Fourth, fifth, and sixth derivatives of position

CAMBRIDGE, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced poster presentations to be made at upcoming medical meetings. Two preclinical poster presentations will be made at the SITC 2022 Annual Meeting being held in Boston, November 8-12. These will include preclinical data on the JTX-1484 program, which targets LILRB4, and a characterization of the expression and function of LILRB receptors on human immune cells in tumor and blood samples across different cancer types. Two clinical poster presentations will be made at the ESMO-IO 2022 Annual Congress being held in Geneva, December 7-9. The submitted abstract for the JTX-8064 INNATE trial contains Phase 1 data, including safety, PK, and tumor response data. Jounce continues to expect to report preliminary clinical data on at least 80 Phase 2 patients from the INNATE trial by end of year 2022. The submitted abstract for the vopratelimab/pimivalimab SELECT trial includes all data previously announced on clinical endpoints. Additional durability data for patients who remain on study will also be reported.

Key Points: 
  • Two preclinical poster presentations will be made at the SITC 2022 Annual Meeting being held in Boston, November 8-12.
  • Two clinical poster presentations will be made at the ESMO-IO 2022 Annual Congress being held in Geneva, December 7-9.
  • The submitted abstract for the JTX-8064 INNATE trial contains Phase 1 data, including safety, PK, and tumor response data.
  • All posters will be available on the Our Pipeline section of the Jounce Therapeutics website after presentation at www.jouncetx.com.

Jounce Therapeutics to Participate in the Upcoming Investor Conferences

Retrieved on: 
Wednesday, September 7, 2022
LILRB2, Cancer, CCR8, Tumor microenvironment, Therapy, NASDAQ, Macrophage, ILT4, Gilead Sciences, PD-1, GLOBE, SELECT, Conference, Immune system, Investor, Hematology, Immunity (medical), ICOS, Patient, Pharmaceutical industry, Fourth, fifth, and sixth derivatives of position

CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that company management will participate in the following upcoming investor conferences in September:

Key Points: 
  • CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that company management will participate in the following upcoming investor conferences in September:
    H.C. Wainwright 24th Annual Global Investment Conference: Fireside chat on Monday, September 12, 2022 at 10:00 a.m.
  • Cantor Oncology, Hematology & HemeOnc Conference: Panel titled, Tackling the Tumor Microenvironment and Further Arming the Immune System on Wednesday, September 28, 2022 at 2:35 p.m.
  • Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform.
  • Pimivalimab is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounces broader pipeline.

Jounce Therapeutics Reports Results from Phase 2 Randomized SELECT Trial Testing 2 Different Doses of Vopratelimab in TISvopra Biomarker-Selected Patients

Retrieved on: 
Tuesday, August 30, 2022
LILRB2, Inflammation, PR, Security (finance), COVID-19, Cis, Induction, PFS, U.S. Securities and Exchange Commission, CCR8, Cancer, Safety, Tumor microenvironment, Research, RNA, Therapy, Macrophage, ILT4, CR, Gilead Sciences, Private Securities Litigation Reform Act, ESMO, SD, CD4, PD-1, Association, ORR, SELECT, Immunotherapy, Immune system, NSCLC, Immunoglobulin G, Marketing, Intellectual property, Public expenditure, PD-L1, Annual report, Congress, ICOS, Patient, Pharmaceutical industry, Fourth, fifth, and sixth derivatives of position

CAMBRIDGE, Mass., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today reported top line data from the randomized Phase 2 SELECT trial evaluating vopratelimab (vopra), Jounce’s inducible costimulator (ICOS) agonist, in combination with pimivalimab (pimi) versus pimivalimab alone in immunotherapy naïve, TISvopra biomarker-selected, second line non-small cell lung cancer (NSCLC) patients. The trial tested two pulsatile and differentiated doses of vopra in the combination groups against pimi monotherapy, using as the primary endpoint the mean percent change from baseline in tumor size in all measurable lesions, averaged over 9 and 18 weeks as assessed by central independent radiology review. As the study was powered to detect a 20% absolute difference of the pooled combo doses compared to pimi monotherapy, and the actual difference was 7%, SELECT did not meet its primary endpoint.   In the combination dose cohort with the lowest dose of vopra (0.03mg/kg), interesting trends were observed in both the primary endpoint, with an absolute mean change of 15%, and in the prespecified secondary endpoints of overall response rate (ORR), which was 40% compared to 25% in pimi alone, and landmark six month progression free survival (PFS) of 80% compared to 33% with pimi alone. Consistent with these clinical outcomes, recent mechanistic data in primary human immune cells in vitro supports shorter duration pulsatile dosing of ICOS agonism, with general implications for T cell agonist dosing. Data from SELECT is summarized as follows:

Key Points: 
  • The distribution of PD-L1 scores within the TISvopra positive patients was similar to what would be expected for an unselected patient population.
  • The team did an outstanding job executing on a complex biomarker selected trial impacted by both the pandemic and the war in Ukraine.
  • Pimivalimab is also being assessed in the SELECT Phase 2 clinical trial (NCT04549025) in combination with vopratelimab.
  • Although Jounce believes that the expectations reflected in the forward-looking statements are reasonable, Jounce cannot guarantee such outcomes.